NEW YORK (GenomeWeb News) - Elan Pharmaceuticals has joined the MetaTox Consortium, a group spearheaded by informatics firm GeneGo that aims to address the reasons behind the failure of investigational drugs in clinical trials.
GeneGo said the consortium includes members from industry and the US Food and Drug Administration and will focus on using systems biology tools and informatics to assess the safety of small molecule compounds and therapeutics.
The group will focus its efforts on developing predictive models, increasing toxicity knowledge, and developing data analysis software for use in systems biology, GeneGo said.